Market news
Every market development we have covered, newest first.
4 dated market items. Most recent: Generic semaglutide launches abroad; US patients wait until 2031 (2026-08-06).
For context: across 32 tracked tirzepatide telehealth programmes, 17 publish a price we could capture, and the cheapest verified all-in cost is $215 a month at a 10 mg maintenance dose — about $2,580 for a first year. Compounded preparations are not FDA-approved. Prices captured 2026-08-05.
All-in monthly cost at 10 mg
Stories in this category
Generic semaglutide launches abroad; US patients wait until 2031
Indian generics started near $8 a month in March. The FDA has tentatively approved a US version …
Ro and WeightWatchers Clinic now carry brand only
Two of the largest consumer platforms stopped selling compounded tirzepatide during 2026, with m…
Microdose protocols spread, and they are not comparable to standard dosing
Fractional-dose plans at lower prices do not map onto the 2.5–15 mg ladder every comparison uses…
Hims closes its compounded GLP-1 programme to new patients
Following a settlement with Novo Nordisk, one of the largest platforms exits compounded semaglut…
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.